Clarivate plc — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Clarivate provides information, analytics, professional services, and workflow software serving Academia & Government (A&G), Intellectual Property (IP), and Life Sciences & Healthcare (LS&H). The filing covers the three months ended March 31, 2024; amounts are in millions except per-share data.
Key Financial Metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $621.2 | $629.1 | (1.3)% |
| Operating income | $5.0 | $54.6 | Down $49.6 |
| Net income (loss) | $(75.0) | $43.5 | Down $118.5 |
| Net income (loss) attributable to ordinary shares | $(93.8) | $24.7 | Down $118.5 |
| Basic and diluted EPS | $(0.14) | $0.04 | Unfavorable |
| Adjusted EBITDA | $236.3 | $252.7 | (6.5)% |
| Adjusted EBITDA margin | 38.0% | 40.2% | Down 220 bps |
| Net cash from operating activities | $176.2 | $227.5 | (23)% |
| Free cash flow | $111.8 | $168.2 | (34)% |
Subscription revenue increased 2.5% to $403.1, while re-occurring revenue declined 4.8% to $102.5 and transactional and other revenue declined 9.8% to $115.6. Annualized contract value was $1,583.3, up 1.8%, and the annual renewal rate remained 93%.
Revenue by segment was $317.7 for A&G, $200.9 for IP, and $102.6 for LS&H. A&G increased 1.0%, while IP declined 3.9% and LS&H declined 2.6%.
Cash and cash equivalents, including restricted cash, were $361.8 on the balance sheet at March 31, 2024. Management reported $691.5 of available revolving-credit capacity. Long-term debt was $4,637.9; total debt outstanding before discounts and issuance costs was $4,722.6. Interest expense was $70.2.
Material Changes Versus the Prior Comparable Period
- Revenue declined modestly, primarily because of lower patent-renewal volumes in IP and lower transactional activity in A&G and LS&H.
- Operating income fell substantially because Q1 2024 included a $15.8 loss on the divestiture of a small IP product group, whereas Q1 2023 benefited from a $49.4 legal-settlement gain.
- Q1 2024 included a $15.0 income-tax provision, compared with a $63.6 tax benefit in Q1 2023, which included a $70.4 benefit from settling an open tax dispute.
- Adjusted EBITDA and margin declined despite lower cost of revenues and SG&A, reflecting revenue pressure and unfavorable operating items.
- Operating cash flow decreased by $51.3, driven by lower operating income and working-capital timing. Capital expenditures increased to $64.4 from $59.3.
- In January 2024, Clarivate refinanced its credit facilities, extended the term-loan maturity to 2031, reduced the revolving facility from $750.0 to $700.0, and prepaid $47.4 of prior term loans.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
The filing does not provide a clear new quantitative revenue or earnings guidance outlook. Management stated that operating cash flow, cash on hand, borrowing capacity, and access to capital markets are expected to be adequate for debt service, liquidity needs, capital expenditures, and business plans for the next 12 months and foreseeable future.
- The Segment Optimization Program generated $9.5 of restructuring expense in Q1 2024. Approximately $11 of additional costs are expected, primarily during 2024.
- A product-group divestiture closed April 1, 2024 for approximately $34 payable over ten years; the company recognized a $15.8 pre-closing loss in Q1.
- The 5.25% mandatory convertible preferred shares are scheduled to convert into ordinary shares on June 1, 2024. Approximately $20 of preferred dividends were expected to be paid in Q2 before conversion.
- There were 17.8 million private-placement warrants outstanding at March 31, 2024, with an $11.50 exercise price and expiration in May 2024. Their recorded liability was zero at quarter-end.
- Management disclosed a material weakness in internal control over financial reporting relating to the preparation and review of footnote disclosures. Remediation activities were implemented in Q4 2023, but the weakness had not been deemed remediated as of March 31, 2024.
- Pending securities-related class actions remain unresolved. The company stated that it cannot estimate any reasonably possible loss or range of loss because of the early stage of the proceedings.
- Key ongoing risks include high leverage and interest-rate exposure, foreign-currency volatility, cybersecurity and data-privacy risks, competition, customer renewals, reliance on third-party data, AI-related regulatory and technology risks, intellectual-property protection, and acquisition or divestiture execution.
Important Facts for Investors to Verify
- Reconcile the reported debt amounts, including the balance-sheet long-term debt, total debt outstanding, lease obligations, and available revolver capacity.
- Monitor the June 1, 2024 preferred-share conversion, related dilution, and the approximately $20 of expected preferred dividends.
- Confirm the May 2024 expiration or exercise status of the 17.8 million private-placement warrants.
- Assess whether the Segment Optimization Program delivers expected savings and whether additional restructuring charges remain consistent with management’s estimate.
- Track remediation and auditor or management conclusions regarding the material weakness in financial-reporting controls.
- Evaluate whether the decline in IP patent-renewal volumes and transactional revenue persists, and whether subscription growth and pricing offset those pressures.
- Review developments in the pending securities litigation and any resulting financial exposure.